O’Melveny Represents Belite Bio in Follow-on Offering
June 7, 2023
FOR IMMEDIATE RELEASE
SHANGHAI, JUNE 7, 2023 —O’Melveny recently represented Belite Bio, Inc (NASDAQ: BLTE) in connection with its follow-on offering of two million ADSs and warrant to purchase two million ordinary shares represented by ADSs. The total gross proceeds of the offering were US$30 million before the exercise of any warrant. Belite Bio filed its registration statement on Form F-3 with the SEC on May 22, 2023 and priced on May 30, 2023. The closing took place on June 2, 2023.
Headquartered in San Diego, Belite Bio is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting retinal degenerative eye diseases with significant unmet medical needs, such as Stargardt disease and Geographic Atrophy in advanced dry age-related macular degeneration, in addition to specific metabolic diseases.
SVB Securities LLC, Cantor Fitzgerald & Co. and H.C. Wainwright & Co., LLC are acting as joint book-running managers for the offering.
The O’Melveny team advising Belite Bio was led by partners Portia Ku and Vincent Lin, counsel Jane Wu, associate Qianru Hong, and legal consultant Yutong Xie. Partners Jeeho Lee, Rob Plesnarski, Kurt Berney and Shelly Heyduk advised on SEC related issues, and partner Robert Fisher, partner Billy Abbott and counsel Dawn Lim provided tax-related advice.
O’Melveny previously represented the company on its IPO and pre-IPO financings.
It’s more than what you do: it’s how you do it. Across sectors and borders, in board rooms and courtrooms, we measure our success by yours. And in our interactions, we commit to making your O’Melveny experience as satisfying as the outcomes we help you achieve. Our greatest accomplishment is ensuring that you never have to choose between premier lawyering and exceptional service. So, tell us. What do you want to achieve? Visit us at www.omm.com; read our Insights 2023 report; hear what our lawyers, business professionals, and clients have to say in the “Our DNA” video series, learn more in our firm at-a-glance; and find us on LinkedIn, Twitter, Facebook, Instagram, and YouTube.
O’Melveny & Myers LLP
+1 213 430 8024
O’Melveny & Myers LLP
+86 21 2307 7000
# # #